NIKKEI 225
26,871.27 +379.30 (+1.43%) HANG SENG
22,201.57 +482.51 (+2.22%) CRUDE OIL
107.48 -0.14 (-0.13%) GOLD FUTURES
1,837.70 +7.40 (+0.40%) DOW
31,500.68 +823.28 (+2.68%) BTC-GBP
17,275.56 -293.22 (-1.67%)
Heidelberg Pharma AG (0QW5.L)
| Previous close | 4.7118 |
| Open | 4.7000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 4.6500 - 4.7000 |
| 52-week range | 4.6500 - 4.7000 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 120.508M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7830 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure
Heidelberg Pharma AG / Key word(s): Corporate ActionHeidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure 09-May-2022 / 16:39 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY
- EQS Group
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022
DGAP-News: Heidelberg Pharma AG / Key word(s): Interim ReportHeidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022 28.04.2022 / 07:14 The issuer is solely responsible for the content of this announcement.Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022- Start of clinical trial with HDP-101 in multiple myeloma- Financing commitment of up to EUR 36 million obtained from main shareholder dievini- Signing of a strategic partnership w
- EQS Group
Heidelberg Pharma to Present New Data on its Proprietary ATAC(R) Technology Platform at the AACR Annual Meeting 2022
DGAP-News: Heidelberg Pharma AG / Key word(s): Conference07.04.2022 / 14:05 The issuer is solely responsible for the content of this announcement.PRESS RELEASEHeidelberg Pharma to Present New Data on its Proprietary ATAC(R) Technology Platform at the AACR Annual Meeting 2022Ladenburg, Germany, 7 April 2022 - Heidelberg Pharma AG (FSE: HPHA) announced today that it will present preclinical data on its proprietary Amanitin-based ATAC(R) technology at the American Association for Cancer Research (A
